GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, CTLA-4, TIGIT, TIM-3, GITR, PD-L1, B7-H3, TLR2 and TLR4.

Read the full press release.